Form D · Other Health Care
Savannah Therapeutics, Inc
Riverdale, MD · CIK 0002149298
Offering snapshot reported Sep 11, 2026 · SEC filing
- Reported sold
- $3.86M Offering amount: $6M
- Investors reported
- 28 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Apr 17, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 11, 2026 | Initial | $3,855,000 | No comparison | 28 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-597238
None
Source: Form D, filed Sep 11, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Matthew Dowling | Director |
| Thomas Wollan | Executive |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
5650 Rivertech Court Suite 20
Riverdale, MD, 20737
Riverdale, MD, 20737